Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,696.42 -447.85 (-0.70%) CMC Crypto 200
1,321.75 -74.78 (-5.35%)
ABBV Jun 2024 175.000 call
- Zacks
PCE In-Line to Warmer, Pre-Market Calms; ABBV Beats, XOM Misses
Pre-market futures are up across the board: +106 points on the Dow, +45 points on the S&P 500 and +195 on the Nasdaq immediately following this important data's release.
- Zacks
AbbVie (ABBV) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- Barrons.com
AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Drop
AbbVie raised its full-year earnings outlook despite continuing sales declines for autoimmune drug Humira. AbbVie said it expects adjusted earnings in 2024 of between $11.13 and $11.33 a share, up from previous guidance of $10.97 to $11.17 a share. Analysts surveyed by FactSet were expecting the biopharmaceutical company to post full-year earnings of $11.12 a share.
